Biogen Idec Inc (BIIB) 311.94 $BIIB Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board

Jul 29, 2015 at 12:21 PM

Biogen Idec Inc (BIIB) 311.94 $BIIB

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - 33 mins ago
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 311.94 (-7.99), VRTX: 128.32 (+0.02), ALXN: 202.92 (-0.63), AMGN: 171.81 (-0.93), ABBV: 71.29 (+0.06), REGN: 541.87 (-10.58), XOMA: 0.83 (-0.05)

Make Sure You Don't Get Caught in a Breakdown
at The Street - 2 hrs 10 mins ago
Nothing much sticks out to the upside right now.
BIIB: 311.94 (-7.99), ESPR: 65.31 (-3.70), VDSI: 21.17 (-5.38), FB: 95.51 (+0.22), BEAT: 11.83 (-0.16), DATA: 103.86 (-23.21)

Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - 2 hrs 11 mins ago
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 311.94 (-7.99), F: 15.09 (+0.26), RIG: 14.33 (+0.21), GILD: 116.89 (+3.82), PFE: 35.75 (+0.40), COP: 52.85 (+0.61), XOM: 82.66 (+0.18), AMGN: 171.81 (-0.93), DD: 56.17 (+0.27), CVX: 92.76 (+0.36), SLB: 83.51 (+1.01), UPS: 101.78 (+1.84), CELG: 133.94 (-1.48)

5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 73.12 (+0.22), ZINC: 8.09 (+0.19), BIIB: 311.94 (-7.99), MJN: 89.79 (-0.30), DPZ: 112.16 (+0.39)

Biogen Stock Remains Deeply Oversold
at The Street - Wed Jul 29, 5:00AM CDT
Three ways to profit after last Friday's crazy freefall.
BIIB: 311.94 (-7.99)

Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
at The Street - Tue Jul 28, 3:15PM CDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82)

Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 337.84 (-1.66), BIIB: 311.94 (-7.99), SHPG: 267.16 (+3.91), MYL: 57.06 (+0.71), AMGN: 171.81 (-0.93), ABBV: 71.29 (+0.06), TEVA: 71.16 (-0.25)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"

(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
BIIB: 311.94 (-7.99)

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 157.02 (-3.30), BIIB: 311.94 (-7.99), LGND: 103.18 (-2.66), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32)

Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 311.94 (-7.99), TEVA: 71.16 (-0.25)

3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82), CELG: 133.94 (-1.48)

Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 311.94 (-7.99)

'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.46 (+0.06), MMM: 151.31 (+0.20), BIIB: 311.94 (-7.99), ISIS: 53.20 (-1.20), MDSO: 54.08 (-0.16), COP: 52.85 (+0.61), SNDK: 60.64 (-0.44)

Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.46 (+0.06), MMM: 151.31 (+0.20), AMZN: 527.32 (+1.29), BIIB: 311.94 (-7.99), MDLZ: 42.98 (+0.18), EA: 71.42 (-0.38), SNA: 162.96 (+1.83), NKE: 114.31 (+0.84), MDSO: 54.08 (-0.16), FB: 95.51 (+0.22), FCX: 12.33 (unch), COP: 52.85 (+0.61), DIS: 119.42 (+0.96), NFLX: 107.34 (+0.44), ISIS: 53.20 (-1.20), QLIK: 39.87 (-0.80), KHC: 77.11 (-1.21), GOOGL: 656.11 (-3.55), ULTA: 166.12 (+0.11), CMCSA: 62.42 (+0.01), GIS: 57.47 (-0.08), SNDK: 60.64 (-0.44)

Which Big-Cap Stocks Are Defying Market Pressure?
at Investor's Business Daily - Mon Jul 27, 5:46PM CDT
When an uptrend comes under pressure, some stocks show action worthy of a drumroll, while others inspire eye rolls. The recent trouble for the uptrend started after the July 20 close. The S&P 500 suffered four distribution days in a row through...
BIIB: 311.94 (-7.99), MNST: 149.64 (-0.35), VRX: 255.33 (-2.62), GILD: 116.89 (+3.82), CMG: 737.61 (+6.83)

5 Things Biogen's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 27, 5:00PM CDT
Biogen held a conference call in conjunction with its second-quarter earnings last week. Here are five things that management said that investors should be paying attention to. "We had expected to see a reacceleration of Tecfidera this quarter,...
BIIB: 311.94 (-7.99)

Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 337.84 (-1.66), BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82), TEVA: 71.16 (-0.25), TWTR: 31.80 (-4.74)

Is the U.S. Bull Market Starting to Lose Its Luster?
at The Street - Mon Jul 27, 2:04PM CDT
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
BIIB: 311.94 (-7.99), PRGO: 193.10 (+1.03), XOM: 82.66 (+0.18), MYL: 57.06 (+0.71), BMY: 64.50 (-0.16), AGN: 337.84 (-1.66), ISRG: 540.37 (+0.11), SBUX: 57.33 (+0.19), HCA: 93.77 (+1.48), IBM: 160.93 (+0.88), GM: 31.74 (+0.42), TEVA: 71.16 (-0.25), SPLK: 68.15 (-2.74), REGN: 541.87 (-10.58), NVS: 103.83 (+1.04)

4 Stocks Breaking Out on Big Volume
at The Street - Mon Jul 27, 1:30PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
BIIB: 311.94 (-7.99), TERP: 30.73 (-0.52), WAB: 100.64 (+1.02), ENTA: 47.40 (-0.65)

Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
at The Street - Mon Jul 27, 11:32AM CDT
Tech stocks were on the minds of viewers Monday morning when they posed their questions to TheStreet's Jim Cramer, including Intel, T-Mobile and PayPal.
BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82), ALTR: 49.42 (-0.06), XON: 60.63 (+0.03), PYPL: 37.91 (+0.31), TMUS: 37.00 (+0.08), TWTR: 31.80 (-4.74), INTC: 29.05 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Alex Jones Returns to Austin: New Studio, New Plans

Back in the Saddle: Austin's Controversy Stirs Again It looks like we're seeing a new chapter in a saga that just refuses to end. Alex Jones, the infamous firebrand who's plastered conspiracy theories across the airwaves for two decades, is returning to ground zero in Austin—the old InfoWars studio. After wading through bankruptcy muck and courtroom clashes, Jones is...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Stravito's MCP Server Revolutionizes AI in Business

We're seeing another big swing in how enterprises weave AI into the fabric of decision-making. Stravito, an enterprise customer intelligence platform, launched its Model Context Protocol (MCP) Server. This thing brings company-owned research right into the gizmos teams already use. Now, businesses aren't left groping in the dark figuring out their next moves—pretty...

Subaru, Motorq Offer Hardware-Free Fleet Telematics Insights

An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Quantum Sky's Strategic Leadership Overhaul Targets Growth

Executive Shake-Up Aims for Stronger Federal Market Alignment Buckle up, folks—there's some major chess-piecing happening at Quantum Sky. They've just named not one or two, but three executive bigwigs to head up their core business groups. This isn’t just some ceremonial reshuffle. Nah, it’s bigger. They're redefining how they tackle the Department of War, Intel &...

NORD Honors Innovators Shaping Rare Disease Treatment

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...